Abouir Kenza, Samer Caroline F, Gloor Yvonne, Desmeules Jules A, Daali Youssef
Division of Clinical Pharmacology and Toxicology, Department of Anesthesiology, Pharmacology, Intensive Care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland.
Institute of Pharmaceutical Sciences of Western Switzerland (ISPSO), University of Geneva, Geneva, Switzerland.
Front Pharmacol. 2021 Oct 28;12:708299. doi: 10.3389/fphar.2021.708299. eCollection 2021.
Physiologically-based pharmacokinetics (PBPK) modeling is a robust tool that supports drug development and the pharmaceutical industry and regulatory authorities. Implementation of predictive systems in the clinics is more than ever a reality, resulting in a surge of interest for PBPK models by clinicians. We aimed to establish a repository of available PBPK models developed to date to predict drug-drug interactions (DDIs) in the different therapeutic areas by integrating intrinsic and extrinsic factors such as genetic polymorphisms of the cytochromes or environmental clues. This work includes peer-reviewed publications and models developed in the literature from October 2017 to January 2021. Information about the software, type of model, size, and population model was extracted for each article. In general, modeling was mainly done for DDI prediction via Simcyp software and Full PBPK. Overall, the necessary physiological and physio-pathological parameters, such as weight, BMI, liver or kidney function, relative to the drug absorption, distribution, metabolism, and elimination and to the population studied for model construction was publicly available. Of the 46 articles, 32 sensibly predicted DDI potentials, but only 23% integrated the genetic aspect to the developed models. Marked differences in concentration time profiles and maximum plasma concentration could be explained by the significant precision of the input parameters such as Tissue: plasma partition coefficients, protein abundance, or Ki values. In conclusion, the models show a good correlation between the predicted and observed plasma concentration values. These correlations are all the more pronounced as the model is rich in data representative of the population and the molecule in question. PBPK for DDI prediction is a promising approach in clinical, and harmonization of clearance prediction may be helped by a consensus on selecting the best data to use for PBPK model development.
基于生理的药代动力学(PBPK)建模是一种强大的工具,可支持药物研发以及制药行业和监管机构。临床中预测系统的应用比以往任何时候都更加切实可行,这使得临床医生对PBPK模型的兴趣激增。我们旨在建立一个现有PBPK模型的储存库,这些模型是迄今为止通过整合细胞色素基因多态性或环境线索等内在和外在因素而开发的,用于预测不同治疗领域的药物相互作用(DDI)。这项工作涵盖了2017年10月至2021年1月期间同行评审的出版物以及文献中开发的模型。针对每篇文章提取了有关软件、模型类型、规模和群体模型的信息。总体而言,建模主要通过Simcyp软件和全PBPK进行DDI预测。总体而言,相对于药物吸收、分布、代谢和消除以及模型构建所研究的群体而言,诸如体重、体重指数、肝或肾功能等必要的生理和生理病理参数是公开可用的。在46篇文章中,32篇合理地预测了DDI潜力,但只有23%的文章在开发的模型中纳入了遗传因素。浓度-时间曲线和最大血浆浓度的显著差异可以通过输入参数(如组织:血浆分配系数、蛋白质丰度或Ki值)的显著精度来解释。总之,这些模型在预测血浆浓度值和观察到的血浆浓度值之间显示出良好的相关性。随着模型富含代表所研究群体和相关分子的数据,这些相关性会更加明显。用于DDI预测的PBPK在临床中是一种很有前景的方法,对清除率预测的统一可能有助于就选择用于PBPK模型开发的最佳数据达成共识。